Sex Differences in the Vascular Effects of E-cigarette Use

Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-24
SponsorAnna Stanhewicz, PhD

About this trial

The use of electronic nicotine delivery systems, or e-cigarettes - colloquially referred to as "vaping" - in the United States has increased exponentially since their introduction to the US market in 2007. Prevalence of ever and current e-cigarette use is highest among teenagers and young adults with 16-28% of this population having reported vaping. While the majority of e-cigarette users are current tobacco smokers, 32.5% of current e-cigarette users are never- or former-smokers, representing a growing population of young adults who exclusively vape. While e-cigarettes have been marketed as a safer alternative to tobacco cigarettes, clinical studies examining these claims are limited. Cardiovascular disease (CVD) is the primary cause of premature death among tobacco cigarette smokers and reductions in vascular endothelial function, a significant predictor of future CVD, are detectible in otherwise healthy young adults who smoke. Despite the explosion in e-cigarette use among young adults, the health effects - especially the effects on mechanisms of vascular function - of these devices remain relatively unexplored.

In this study, we use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) we examine the blood vessels in a dime-sized area of the skin in otherwise healthy young (18-24yrs) chronic e-cigarette users. Local heating of the skin at the microdialysis sites is used to explore differences in mechanisms governing microvascular control. As a compliment to these measurements, we also draw blood from the subjects to measure circulating factors that may contribute to cardiovascular health and examine markers of inflammatory activation. We will also collect urine from female participants to measure estradiol.

Eligibility criteria

Qualifiers

18-24 years old

have no history of e-cigarette use

be a current e-cigarette user who has been using e-cigarettes for 6 months or longer

Disqualifiers

history of cardiovascular, metabolic, and/or skin diseases

body mass index >30 kg/m2

blood pressure ≥140 systolic and/or ≥ 90 diastolic

current or history of tobacco cigarette use

Trial design

Treatments tested in this trial

  • Local heating + L-NAME (NG-nitro-L-arginine methyl ester; nitric oxide synthase inhibitor)
  • Chronic estrogen exposure

Treatment groups

80 Participants
are divided into 4 treatment groups

Sponsors and collaborators

Anna Stanhewicz, PhD

Lead sponsor

University of Iowa

Sponsor institution